Request Trial
10 December 2013Pharma

IP Summit: What does the UPC hold for the pharma and chemical industries?

At the PanEuropean IP Summit on Tuesday, a panel discussion revealed different attitudes toward the introduction of the Unitary Patent and Unified Patent Court (UPC).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
Teva faces scrutiny over efforts to curb generic competition
27 August 2026   Turkish regulators are investigating the drugmaker over its efforts to protect its drug from generic rivals—conduct that may sound familiar to European competition watchers.
Pharma
Teva and Aurinia settle generics dispute over lupus drug, voclosporin
21 August 2026   Under the terms of the agreement, which resolves all patent litigation between the biopharma rivals, Teva now has a launch date for its own version of Aurinia's Lupkynis.
Pharma
SK Biopharmaceuticals settles epilepsy generic dispute
20 August 2026   A reported deal with an Indian manufacturer could clear a path for a future generic launch as the Korean drugmaker leverages one of its biggest US products.


Editor's picks

Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
Biotech
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
1 September 2026

Editor's picks

Biotech
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
1 September 2026

More features

G 1/25: EPO settles controversial patent description question
California votes for law to restrict use of genAI by lawyers
10x Genomics wins latest round in Parse patent dispute
Sun Pharma import ban back in force after Squires intervention
White & Case life sciences co-leader moves firms
‘Busiest’ US district patent judge swaps bench for private practice
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
Pinsents expands German patent practice with partner duo